CompletedPhase 1NCT01226849

Feasibility Study Of Adding Bortezomib to R-ICE Chemotherapy To Treat Relapsed/ Refractory Diffuse Large B-Cell Lymphoma

Studying Diffuse large B-cell lymphoma with chronic inflammation

Last synced from ClinicalTrials.gov

Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing data

Key facts

Sponsor
Singapore General Hospital
Principal Investigator
Yeow Tee Goh, MBBS MMed
Singapore General Hospital
Intervention
bortezomib, rituximab, ifosphamide, etoposide, carboplatin(drug)
Enrollment
6 target
Eligibility
21 years · All sexes
Timeline
20102014

Study locations (1)

Collaborators

Janssen-Cilag Ltd.

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Open NCT01226849 on ClinicalTrials.gov

Other trials for Diffuse large B-cell lymphoma with chronic inflammation

Additional recruiting or active studies for the same condition.

See all trials for Diffuse large B-cell lymphoma with chronic inflammation

← Back to all trials